ALLIANCE DISCOVERY INC — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Evidence in pre-clinical and clinical settings sugges
ALLIANCE DISCOVERY INC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $224,748
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- PA
- Period
- —
Description
DESCRIPTION (provided by applicant): Evidence in pre-clinical and clinical settings suggests the involvement of chemokines in metastatic tumor cell disease spreading. We have recently provided data validating the involvement of the CX3CR1/Fractalkine axisin breast and prostate cancer metastasis. We have discovered a potent in vivo efficacious drug-like small molecule using in vitro chemotaxis and functional assays to provide pharmacological proof of concept that modulation of the CX3CR1/ Fractalkine axis with a small molecule CX3CR1 antagonist may have therapeutic benefit in the treatment of advanced breast and prostate cancer. Specific aims of this proposal are: Aim 1: To provide an improved drug-like CX3CR1 antagonist. The lead compound, JMS-17-2, will beoptimized using medicinal chemistry approaches; maintaining potency, improving selectivity, and optimizing in vitro pharmacokinetic properties and the resulting optimized lead from this aim will be evaluated for in vivo pharmacokinetics in mice and u